AKTX
Akari Therapeutics, Plc
NASDAQ · Healthcare · Biotechnology · GB
$11.77
+8.58%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 4.9M | 2.8M | 7.0M | 8.0M | 9.6M |
| SG&A Expense | 8.8M | 9.3M | 9.7M | 11.4M | 13.5M |
| General & Admin Expense | 8.8M | 9.3M | 9.7M | 11.4M | 13.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 17.3M | 5.2M | 5.0M | (2.6M) | — |
| Total Operating Expenses | 31.0M | 17.3M | 21.6M | 16.8M | 23.1M |
| Cost and Expenses | 31.0M | 17.3M | 21.6M | 16.8M | 23.1M |
| Operating Income (EBIT) | (31.0M) | (17.3M) | (21.6M) | (16.8M) | (23.1M) |
| Non-Operating | |||||
| Interest Income | 993.99 | 1.0K | 8.0K | 82.0K | 45.9K |
| Interest Expense | 984.3K | 949.0K | (244.0K) | — | — |
| Net Interest Income | (983.3K) | (948.0K) | 252.0K | 82.0K | 45.9K |
| Other Non-Op Income/Expense | (1.8M) | (1.0M) | 1.9M | 6.8M | 5.3M |
| Non-Operating Income (excl Interest) | 846.0K | 77.0K | (2.1M) | (6.8M) | (5.3M) |
| EBT (Pre-Tax Income) | (32.8M) | (18.3M) | (19.8M) | (10.0M) | (17.7M) |
| Income Tax Expense | (1.9M) | (1.0M) | — | — | — |
| Bottom Line | |||||
| Net Income | (31.0M) | (17.3M) | (19.8M) | (10.0M) | (17.7M) |
| Earnings from Cont. Ops | (31.0M) | (17.3M) | (19.8M) | (10.0M) | (17.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (31.0M) | (17.3M) | (19.8M) | (10.0M) | (17.7M) |
| Per Share | |||||
| Basic EPS | ($1,600.00) | ($20,800.00) | ($132,800.00) | ($163,200.00) | ($455,200.00) |
| Diluted EPS | ($1,600.00) | ($20,800.00) | ($132,800.00) | ($163,200.00) | ($455,200.00) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 1.8M | 21040 | 5972 | 2447 | 1560 |
| Diluted Shares Outstanding | 1.8M | 21040 | 5972 | 2447 | 1560 |
| Profitability Metrics | |||||
| EBITDA | (31.8M) | (17.4M) | (19.5M) | (10.0M) | (17.7M) |
| D&A | — | — | 14.0K | 4.0K | 4.0K |
| EBIT | (31.8M) | (17.4M) | (19.5M) | (10.0M) | (17.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026